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Isocyanates, a group of reactive chemicals
[with the functional group N = C = O
(NCO)] used extensively in the production of
numerous polyurethane foams, coatings, and a
wide array of consumer products, are a major
cause of occupational asthma worldwide. The
polyurethane industry has expanded dramati-
cally, along with the number of workers and
consumers at risk for exposure. Inhalation has
long been considered the primary route of
isocyanate exposure, induction of sensitiza-
tion, and asthma; research, practice, and
regulation have focused almost exclusively on
understanding and preventing inhalation
exposures. Airborne isocyanate exposures
have been reduced through improved con-
trols and use of less-volatile isocyanates. Yet
isocyanate asthma continues to occur, not
uncommonly in work settings where meas-
ured isocyanate respiratory exposures are very
low or nondetectable, but where there is
opportunity for skin exposure. 
It has been > 25 years since Karol et al.
(1981) demonstrated in guinea pigs that skin
contact with isocyanates could lead to sensiti-
zation and subsequent asthmatic responses fol-
lowing inhalation exposure. However,
knowledge and awareness remain limited
regarding the potential for isocyanate skin
exposure to contribute to the development of
isocyanate asthma. For example, the literature
on occupational asthma rarely mentions iso-
cyanate skin exposure as a potential risk factor
or target for prevention (Nicholson et al. 2005;
Tarlo and Liss 2005). Over the past several
years there has been a growing, but largely
unrecognized, collection of animal, industrial
hygiene, clinical, and epidemiologic data
related to isocyanate skin exposure and its role
in the development of isocyanate sensitization
and asthma. Our primary purpose in this arti-
cle is to review and synthesize this multi-
disciplinary literature to address several key
unresolved issues, including the extent of
isocyanate skin exposures in the workplace,
the effectiveness of personal protective equip-
ment, and most importantly, whether human
skin exposure contributes to the development
of isocyanate asthma. The ﬁndings may be rel-
evant to the larger issue of the role of skin as
an important underrecognized site of exposure
and sensitization for other environmental
allergens.
Methods
Deﬁnition of terms. The terms “skin exposure”
and “dermal exposure” are used interchange-
ably to indicate exposure to the outermost
layer of the epidermis or epicutaneous expo-
sure, as is commonly done in the occupational
and environmental literature. “Isocyanates”
refers to diisocyanate monomers (two NCO
groups) and their related polyisocyanates,
which have similar health effects (Bello et al.
2004). The term “sensitization” can generate
misunderstanding. “Sensitization” generally
refers to priming of the immune system in
response to a speciﬁc non-self antigen, a condi-
tion that involves immune memory, typically
antigen-specific T cells and/or antibodies.
Subsequent reexposure to the antigen can
result in an immunopathologic adverse reac-
tion, such as a Th2 (T-helper 2)-type acute
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OBJECTIVE: Isocyanates (di- and poly-), important chemicals used worldwide to produce
polyurethane products, are a leading cause of occupational asthma. Respiratory exposures have been
reduced through improved hygiene controls and the use of less-volatile isocyanates. Yet isocyanate
asthma continues to occur, not uncommonly in settings with minimal inhalation exposure but
opportunity for skin exposure. In this review we evaluate the potential role of skin exposure in the
development of isocyanate asthma. 
DATA SOURCES: We reviewed the published animal and human literature on isocyanate skin-
exposure methods, workplace skin exposure, skin absorption, and the role of skin exposure in
isocyanate sensitization and asthma. 
DATA EXTRACTION: We selected relevant articles from computerized searches on Medline, U.S.
Environmental Protection Agency, Occupational Safety and Health Administration, National
Institute for Occupational Safety and Health, and Google databases using the keywords “iso-
cyanate,” “asthma,” “skin,” “sensitization,” and other synonymous terms, and our own extensive
collection of isocyanate publications. 
DATA SYNTHESIS: Isocyanate production and use continues to increase as the polyurethane industry
expands. There is substantial opportunity for isocyanate skin exposure in many work settings, but
such exposure is challenging to quantify and continues to be underappreciated. Isocyanate skin expo-
sure can occur at work, even with the use of personal protective equipment, and may also occur with
consumer use of certain isocyanate products. In animals, isocyanate skin exposure is an efﬁcient route
to induce sensitization, with subsequent inhalation challenge resulting in asthma-like responses.
Several lines of evidence support a similar role for human isocyanate skin exposure, namely, that such
exposure occurs and can contribute to the development of isocyanate asthma in certain settings, pre-
sumably by inducing systemic sensitization. 
CONCLUSIONS: Integrated animal and human research is needed to better understand the role of skin
exposure in human isocyanate asthma and to improve diagnosis and prevention. In spite of substan-
tial research needs, sufﬁcient evidence already exists to justify greater emphasis on the potential risks
of isocyanate skin exposure and the importance of preventing such exposures at work and during
consumer use of certain isocyanate products. 
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115:328–335 (2007). doi:10.1289/ehp.9557 available via http://dx.doi.org/ [Online 28 November
2006]allergic reaction or asthmatic response, or con-
tact hypersensitivity-type reaction, such as
allergic contact dermatitis (Sheaarer and
Fleisher 2003). Others consider sensitization
any immunologic memory of exposure, regard-
less of its pathogenic potential (i.e., a speciﬁc
IgG response) (Abbas et al. 2000). Skin or res-
piratory sensitization typically refers to the
route of exposure that results in systemic sensi-
tization, rather than localized immune
responses at those sites. 
Literature search. We have been active in
the ﬁeld of isocyanate research and have col-
lected > 800 published and unpublished arti-
cles and documents from 1951 to the present;
these articles and documents are related to iso-
cyanates and span many disciplines. In addi-
tion, we performed computerized searches of
the literature on Medline [1966 to the present
(National Library of Medicine, Bethesda,
MD)], National Institute for Occupational
Safety and Health (NIOSH), Occupational
Safety and Health Administration (OSHA)
and U.S. Environmental Protection Agency
(EPA) databases and Google (google.com)
using the key words “isocyanate,” “diiso-
cyanate,” “asthma,” “sensitization,” “expo-
sure,” “dermal,” “skin,” “occupational,”
“methylene diphenyl diisocyanate,” and other
synonymous terms. Additional articles were
identified from the reference lists of the
selected relevant articles. We reviewed primar-
ily English-language articles, as well as selected
articles in German, Danish, and French.
Human and animal articles that addressed iso-
cyanate skin exposure, sensitization, and
health effects were retained for further analy-
sis. We also included clinical, epidemiologic,
and biomarker studies and case reports that
mentioned skin as a potential route of expo-
sure or had low isocyanate air levels based on
exposure data or work processes. 
Results and Discussion
Health effects of isocyanate exposure.
Isocyanates are considered potent respiratory
allergens. Isocyanate asthma is the major health
problem in isocyanate-exposed workers, affect-
ing approximately 1–25% of the exposed pop-
ulation. The most important risk factor is
isocyanate exposure, but the exposure charac-
teristics and host factors involved remain
unclear (Bernstein 1996; Wisnewski et al.
2006). Isocyanates can also cause hypersensitiv-
ity pneumonitis, contact dermatitis, and rhini-
tis, but these outcomes are less commonly
reported (Baur et al. 1994; Musk et al. 1988).
Clinically isocyanate asthma presents simi-
lar to other types of allergic Th2-like asthma:
Isocyanate asthma typically develops after
repeated exposure for months to years, during
which time sensitization to isocyanates is pre-
sumed to occur. Once sensitized, extremely
low respiratory levels of isocyanate can elicit
asthmatic responses. However, unlike for typi-
cal high molecular weight (MW) occupational
allergens or environmental aeroallergens,
research has failed to identify an isocyanate-
speciﬁc immune response in most isocyanate
asthmatics that indicates isocyanate Th2-like
sensitization, such as a radioallergosorbent test
(RAST) or skin prick test, thus hindering diag-
nosis. This difference may reﬂect involvement
of non-IgE mechanisms in isocyanate asthma
pathogenesis, and/or may be related to the
NCO functional group common to all iso-
cyanates that renders them ideal cross-linking
agents (Wisnewski et al. 2006). Unlike high-
MW allergens, isocyanates can react with
amino (NH2, NH), hydroxyl, and sulfhydryl
groups of various proteins and peptides,
including albumin and keratin, to form a
number of different hapten–protein complexes
or antigens (Wisnewski et al. 1999, 2000).
Human isocyanate skin-patch testing has been
used to confirm sensitization in the uncom-
mon person who develops contact hyper-
sensitivity (allergic contact dermatitis) due to
isocyanate skin exposure, but has not been
helpful for detecting the Th2-like sensitization
presumed to lead to isocyanate asthma
(Kanerva et al. 2001). The mechanisms by
which isocyanates cause asthma remain poorly
defined, and lack of a good immunologic
marker and unclear dose–response relation-
ships have hindered diagnosis and prevention
(Wisnewski et al. 2006). The primary focus
here is on the potential for skin exposure to
contribute to the development of isocyanate
asthma rather than pathogenic mechanisms.
However, a better understanding of the role of
skin exposure may help address these key
problems. 
Several observations suggest that skin may
also be an important site of exposure and sensi-
tization. Isocyanate respiratory exposure alone,
without any skin exposure, seems unlikely in
most work settings. Isocyanate asthma occurs
in settings with minimal documented respira-
tory exposures but clear potential for skin
exposure, and splashes and spills have been
reported by workers who subsequently develop
isocyanate asthma (Bernstein et al. 1993;
Lenaerts-Langanke 1992; Liss et al. 1988;
Nemery and Lenaerts 1993; Zammit-Tabona
et al. 1983).
Workplace and environmental isocyanate
exposures. The chemical structures and impor-
tant physicochemical properties of selected
isocyanates are shown in Figure 1 and Table 1.
The major commercial isocyanates are methyl-
ene diphenyl diisocyanate (MDI), toluene
diisocyanate (TDI), and their nonvolatile
polymeric forms pMDI and pTDI, followed
by polymeric hexamethylene diisocyanate
(pHDI) and isophorone diisocyanate (pIPDI).
Isocyanates are reactive chemicals used exten-
sively to make numerous polyurethane and
other commercial products, such as poly-
urethane foams, adhesives, and coatings. They
are found in a wide range of industries, from
construction to medical care. The increasing
use of nonvolatile polyisocyanates has raised
issues related to their measurement, exposure
metrics, and regulation (Bello et al. 2004).
Occupational exposures to isocyanates
occur primarily in the many end-use settings,
as well as in primary production facilities
where exposures are generally better controlled.
The total number of workers currently exposed
to isocyanates is not known. NIOSH’s esti-
mate of 280,000 U.S. workers exposed or
potentially exposed to isocyanates (NIOSH
1996) is undoubtedly higher today, given
industry growth and new applications. Most
commercial isocyanate products are complex
isocyanate mixtures of variable molecular mass,
volatility, and isocyanate content. Workplace
exposures can occur in the form of isocyanate
vapors, aerosols, or both, depending on the iso-
cyanate type as well as the application method
and other factors. Isocyanates are commonly
mixed with various solvents, polyols, and other
substances, such as catalysts and blowing
agents, which may affect isocyanate reactivity,
skin absorption, and health effects.
Although data are limited, environmental
exposures to unreacted isocyanates are also
possible. A number of consumer products
contain unreacted isocyanates, such as glues,
polyurethane coatings, and foam insulation;
domestic use of such products on rare occa-
sion has been reported to trigger asthma
symptoms in individuals previously sensitized
(Carroll et al. 1976; Dietemann-Molard et al.
1991; Peters and Murphy 1971). Based on
patch testing, a few cases of allergic contact
dermatitis have been reported with the use of
consumer products made from isocyanates
and polyurethanes (Alomar 1986; Morgan
and Haworth 2003; Vilaplana et al. 1987).
Certain biomedical products, such as standard
orthopedic casting material, may be a poten-
tial source of skin exposure to unreacted iso-
cyanates for patients and cast technicians
(Legris et al. 1995). Polyurethane foams and
packaging have been reported to contain very
small amounts of unreacted isocyanates
(Gagne et al. 2003; Krone et al. 2003), but
it is unclear whether these products have
any potential to result in skin exposure.
Environmental isocyanate exposures can also
potentially occur from the release of iso-
cyanates into the environment from primary
or secondary production facilities (Darcey
et al. 2002; De Zotti et al. 2000; Orloff et al.
1998), during the transport or storage of iso-
cyanates or polyurethanes (Allport et al.
2003), or during the thermal degradation of
overheated polyurethane products (Boutin
et al. 2006), but these exposures are rarely
reported. Isocyanate releases from end-users,
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idential neighborhoods, are also possible but
rarely reported. It has been hypothesized that
environmental skin exposure to polyurethanes
in childhood has contributed to the increased
prevalence of childhood asthma (Krone and
Klingner 2005), but human isocyanate expo-
sure from such products has not been docu-
mented, and there are numerous other likely
causative factors.
The primary isocyanate exposure routes
are through the respiratory tract and the skin.
Historically, the focus has been on inhalation
exposures. Increased use of less-volatile
MDI and polymeric isocyanates, as well as
improved hygiene practices, have resulted in
reductions in inhalation exposures to volatile
monomer (Bello et al. 2004), thus potentially
increasing the relative importance of skin
exposure. Isocyanate skin exposure could
contribute a signiﬁcant part of the total body
burden. For example, 1% skin absorption of a
small MDI droplet (10 mg) would deliver a
dose approximately 4.5-fold (450%) higher
than the inhalation exposure at the current
short-term UK occupational exposure limit
(15-min, 70 µg NCO/m3) or approxi-
mately 50% of the corresponding 8-hr (20 µg
NCO/m3) standard, assuming 100% lung
retention and a ventilation rate of 7 L/min
(Bello et al. 2004). 
Measuring isocyanate skin exposure.
Quantiﬁcation of isocyanate skin exposure is
important for research, prevention, and con-
trol. Assessment of skin exposure, in general, is
much less developed than that of inhalation
exposure. Skin exposure sampling methods
typically are nonstandardized, have undergone
limited validation, and can be technically chal-
lenging. Isocyanate skin sampling is further
complicated by several factors, including the
reactivity of NCO groups toward skin pro-
teins, water, or other compounds, and the
complexity of most isocyanate exposures.
Biomarkers such as urinary metabolites, if
available, could potentially be used to assess
internal dose, but would not distinguish
between skin and respiratory exposure.
Techniques that have been used to detect
isocyanate skin exposure include SWYPE pads
(Colormetric Laboratories Inc., Des Plains,
IL) (Liu et al. 2000), wipes (Bello et al., in
press), and tape stripping (Fent et al. 2006).
These methods rely on removal of isocyanates
from the skin—usually a period of time after
initial exposure, and can underestimate expo-
sure as a result of losses due to absorption,
chemical reactions, and/or poor removal efﬁ-
ciency (Bello et al. 2005; Wester et al. 1999).
Techniques that quantitate isocyanate
deposited on the skin, such as reagent-
impregnated patches, may overcome some of
these limitations. Recently, extraction of iso-
cyanates from contaminated gloves was used
to measure hand skin exposure to isocyanates
(Pronk et al. 2006). Application of these skin
exposure methods in the workplace has been
limited, and ﬁndings have not been compared
or validated. Workplace isocyanate skin expo-
sure assessment is further complicated by the
frequently sporadic nature of such exposures.
Workplace isocyanate skin exposure.
Numerous isocyanate end uses, such as spray-
ing and application of foams and adhesives,
provide opportunity for isocyanate skin expo-
sure from deposition of aerosols and/or absorp-
tion of vapors. Typical workplace isocyanate
exposure levels are not irritating and give few
warning signs, and skin protective equipment
may not be worn, even when respiratory pro-
tection is used (NIOSH 1999). Skin exposure
may result from direct contact of unprotected
skin or the failure of personal protective equip-
ment, such as gloves. Opportunities for
Bello et al.
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Table 1. Selected physicochemical properties of commercially important isocyanates.
MW VP 
Isocyanatea (g/mol) (mm Hg)b Volatilityc 1 ppm = x mg/m3
HDI 168.2 0.02 Very high 6.88
TDI 174.2 0.02 Very high 7.13
IPDI 222.3 0.0003 Moderate 9.09
MDI 250.3 0.000005 Very low 10.24
VP, vapor pressure. 
aAll isocyanates are liquids at room temperature, except for MDI. bVP at 20°C, except for MDI (25°C); data from Streicher
et al. (1994). cThe higher the volatility, the shorter the residence time of isocyanates on the skin; most polymeric iso-
cyanates (MW ~ 500) are nonvolatile at room temperature.
Figure 1. Chemical structures of selected isocyanates of commercial importance.
MDI
n = 0 – 4
pMDI
2,4-TDI 2,6-TDI
Isocyanurate of 2,4-TDI
TDI-trimethylolpropane adduct
HDI biuret
IPDI isocyanurate
HDI isocyanurate
nisocyanate skin exposure, such as spills,
cleanup, and contact with contaminated
equipment, are well known to workers and
ﬁeld researchers. For example, NIOSH Health
Hazard Evaluations of a variety of work set-
tings have described workers with skin contact
to isocyanates or uncured polyurethane prod-
ucts (NIOSH 1998, 1999). 
Isocyanate products that are not fully cured
are another potential source of isocyanate skin
exposure (Bello et al., in press). It is commonly
believed that isocyanate-containing products
polymerize rapidly, and once the product
appears hardened, no unbound isocyanate
species remain on the surface. However, there
are few published data confirming this. A
recent study demonstrated that curing pro-
ceeded more slowly than expected, with
unbound isocyanate species detected on
painted surfaces for prolonged periods of time
(days to weeks) (Bello et al., in press). Thus,
handling recently cured isocyanate products
could be a source of isocyanate skin exposure.
In addition, release of free isocyanates has been
reported after heating of cured isocyanate
products, as can occur when grinding, cutting,
or sanding such products (Alliance for the
Polyurethanes Industry 2005; Boutin et al.
2006; Littorin et al. 2002). Such tasks could
represent another possible source of isocyanate
skin exposure.
In spite of observational documentation of
workplace isocyanate skin exposures, pub-
lished data documenting such exposure are
surprisingly limited. Isocyanate skin exposure
has been documented qualitatively with col-
orimetric techniques in several work settings
(Liu et al. 2000; NIOSH 1998). Recent stud-
ies have begun to quantitate such exposures.
Fent et al. (2006) detected HDI monomer on
tape strips from an auto-body painter’s unpro-
tected skin. Pronk et al. (2006) recently
reported isocyanate exposure under gloves on
both hands of auto body and industrial spray
painters, with the highest median hand expo-
sure detected during paint mixing (207 and
63 µg NCO, respectively). 
Effectiveness of personal protective equip-
ment. Gloves and protective clothing remain a
primary means of preventing skin exposure in
the workplace, in addition to engineering and
work practice controls. Gloves and protective
clothing are presumed to protect against iso-
cyanate skin exposure, with nitrile gloves con-
sidered preferable to latex. However, data on
the workplace performance of protective gloves
and clothing are limited, and there is evidence
that isocyanates (Liu et al. 2000; Pronk et al.
2006) and solvents (Collin-Hansen et al.
2006) can be detected underneath gloves.
Skin absorption of isocyanates. Animal
studies employing radiolabeled 14C-MDI
have demonstrated absorption of MDI after
skin exposure (Leibold et al. 1999; Vock and
Lutz 1997). However, quantitative data are
limited and may have underestimated absorp-
tion due to technical issues, such as isocyanate
binding to the dressing and skin. Studies doc-
umenting the disappearance of isocyanates
from guinea pig skin with infrared spec-
troscopy also support isocyanate skin absorp-
tion (Bello et al. 2006).
We are not aware of published data directly
confirming isocyanate skin absorption in
humans; however, a number of studies indi-
rectly demonstrate isocyanate skin absorption.
For example, HDI-conjugated keratins have
been identified from human skin biopsies
obtained after epicutaneous application of HDI
(Wisnewski et al. 2000). Patch testing with iso-
cyanate (0.1–1%) can elicit an isocyanate-
speciﬁc skin contact hypersensitivity reaction
that implies isocyanate skin absorption. 
Studies investigating urinary biomarkers of
isocyanate exposure (the corresponding
diamines) have provided additional indirect
evidence for isocyanate skin uptake (Creely
et al. 2006; Kääriä et al. 2001; Maitre et al.
1996). Elevated levels of these urinary bio-
markers have been detected in workers, in spite
of very low or nondetectable documented
inhalation exposures. Greater than 2-fold
higher urinary metabolite concentrations have
been reported for operators with likely skin
contamination compared to those without
(Creely et al. 2006). Maitre et al. (1996) mea-
sured urinary hexamethylene diamine (HDA)
of two HDI-exposed coworkers. Both workers
had similar inhalation exposure as conﬁrmed
by air measurements, but one had considerably
greater HDI skin contact and a 10-fold
increase in urinary levels of HDA. The authors
concluded that HDI seemed to be readily
absorbed through the skin.
Human isocyanate skin absorption likely
depends on a number of factors, in addition to
the extent of isocyanate skin exposure, and
may vary between isocyanates because of dif-
ferences in their physical and chemical proper-
ties, including molecular mass, fat solubility,
and chemical reactivity. Skin absorption can
be enhanced if the barrier properties of skin
have been damaged, such as can occur with
eczema, cuts, hand washing, cosmetics appli-
cations (shaving, waxing), and other condi-
tions (Moody and Maibach 2006; Smith
Pease et al. 2002). In addition, coexposures
such as solvents used in the production of
polyurethane foams, coatings, and spray appli-
cations can be absorbed through the skin
(Boman and Maibach 2000). Such solvents
may enhance isocyanate absorption and also
break through the gloves.
Skin sensitization. Numerous substances—
primarily low-MW haptens, such as metals and
chemicals, and less commonly proteins—are
known to initiate immune responses in the
skin, most commonly hapten-induced contact
hypersensitivity (Kimber and Dearman 2002).
Contact hypersensitivity (allergic contact der-
matitis) following skin exposure to isocyanates
is well documented in animals and in the clini-
cal dermatologic literature, with sensitization
conﬁrmed with patch testing (Goossens et al.
2002; Herrick 2002). Allergic contact dermati-
tis has been reported following skin exposure to
isocyanates and polyurethane products in a
number of different workplace and non-
occupational settings, but has not been consid-
ered common, and is rarely reported in workers
with isocyanate asthma (Alomar 1986; Frick
et al. 2003; Goossens et al. 2002; Wilkinson
et al. 1991). However, allergic contact dermati-
tis may be more common than suspected
because symptoms can be mild, workers being
evaluated for asthma are frequently not asked
about skin problems, and patch testing can be
falsely negative (Frick et al. 2004; Goossens
et al. 2002). 
Much less is known about the role of skin
exposure in inducing Th2-type immune
responses seen in asthma. Recent animal stud-
ies have documented that skin exposure to pro-
teins such as ovalbumin or peanuts can induce
systemic Th2-type sensitization and subse-
quent asthmatic responses (Herrick et al. 2003;
Strid et al. 2005). Limited clinical and epi-
demiologic studies also support a role for skin
exposure to allergens in the development of
Th2-type sensitization and asthma, or of other
immunologic lung diseases such as chronic
beryllium disease (Cummings et al. 2006; Lack
et al. 2003; Saloga and Knop 2000; Smith
Pease et al. 2002; Tinkle et al. 2003). 
Isocyanate skin exposure, sensitization,
and asthma. Animal models. Animal models
using the three major isocyanates MDI, TDI,
and HDI have all employed skin exposure to
induce sensitization, with subsequent inhala-
tion challenge, to create an asthmatic response
in the lungs (Table 2). Skin sensitization with
other chemicals, such as trimellitic anhydride,
followed by inhalational challenge has also
produced asthmatic responses (Vanoirbeek
et al. 2006; Zhang et al. 2004).
Different sensitization and challenge pro-
tocols (variable doses, frequency, timing, for-
mulation, and route of exposure) using
different isocyanates have resulted in variable
pulmonary responses. In spite of these differ-
ences, several common themes emerge from
these animal studies. First, skin has been a
very effective route of inducing sensitization,
sometimes more effective than inhalation
(Ban et al. 2006; Rattray et al. 1994). For
example, Ban et al. (2006) recently evaluated
several different TDI sensitization scenarios
(inhalation, subcutaneous, topical) and chal-
lenge protocols (vapor, tracheal instillation) in
mice. Topical sensitization followed by tra-
cheal instillation of TDI most closely repro-
duced the Th2-type lung inflammatory
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sitization with vapor TDI was not effective. 
Of note, these isocyanate animal models
also demonstrate that a single one-time or
two-time skin exposure with relatively low
concentrations of isocyanates can be sufﬁcient
to induce sensitization (Herrick et al. 2002;
Karol et al. 1981; Rattray et al. 1994).
Additionally, several models have shown para-
doxical dose–response relationships, such that
a lower skin sensitization dose can result in
greater lung inflammation upon inhalation
challenge than a higher sensitization dose, and
that isocyanate-specific antibody responses
may not correlate with asthmatic responses
(Herrick et al. 2002; Vanoirbeek et al. 2004).
The effective skin sensitizing doses in these
studies, typically in the order of 1–100 µmol
NCO (Table 2) delivered as diluted 1–10%
isocyanate solution, represent a few droplets of
a diluted isocyanate product. Comparable
exposures likely occur in the workplace.
Thus, several different animal models in
more than one species clearly demonstrate
that isocyanate skin exposure can induce sys-
temic sensitization, which with subsequent
inhalation exposure can lead to asthma.
Control experiments in which animals
received only skin exposure demonstrate that
isocyanate skin exposure alone does not cause
asthmatic responses (Herrick et al. 2002;
Karol et al. 1981; Vanoirbeek et al. 2004).
Although issues of comparability with
humans are inevitable, such as differences in
skin permeability, much can be learned from
animal models regarding exposure–response
relationships and the mechanisms that lead to
skin sensitization and asthma.
Human studies. Although patch testing
has conﬁrmed contact hypersensitivity follow-
ing human isocyanate skin exposure, direct
evidence that skin exposure leads to Th2-type
sensitization and the subsequent development
of asthma is limited. As noted above, there is
no good test to identify isocyanate sensitiza-
tion in humans. Isocyanate-speciﬁc IgE is pre-
sent in less than half of isocyanate asthmatics
(Mapp et al. 2005; Wisnewski et al. 2006),
and isocyanate-specific IgG appears to be
indicative primarily of exposure (Liss et al.
1988; Welinder et al. 1988; Wisnewski et al.
2006). Isocyanates are considered a potent
respiratory sensitizer in humans, based largely
on circumstantial evidence rather than on
clear demonstration that respiratory exposure
alone (without associated skin exposure) leads
to isocyanate asthma.
Indirect evidence from a growing number
of case reports and clinical and epidemiologic
studies suggests that isocyanate skin exposure
occurs in the workplace and can increase the
risk for sensitization and isocyanate asthma.
Isocyanate asthma and/or sensitization
(MDI-IgE) have been reported in several case
studies of workers who applied MDI-based
orthopedic casts (Donnelly et al. 2004; Legris
et al. 1995; Sommer et al. 2000). Allergic con-
tact urticaria and asthma following direct hand
contact with MDI glue has been documented
based on a positive MDI-IgE, MDI patch test,
and MDI inhalation challenge (Valks et al.
2003). Consistent across these case reports is
the development of MDI asthma in settings
where skin exposure to MDI occurred and
where MDI air levels, if measured, were non-
detectable or extremely low and opportunity
for MDI respiratory exposure was very limited.
These cases strongly suggest that skin exposure
was the predominant exposure route and con-
tributed to the development of isocyanate sen-
sitization and asthma. They also demonstrate
that isocyanate asthma can occur in settings
where measured isocyanate respiratory expo-
sures are below the level of detection, even
when sensitive analytical methods are used.
Skin exposure has also been implicated as
a risk factor for isocyanate asthma in several
epidemiologic studies of MDI-exposed work-
ers, in which measured inhalation exposures
were all very low or nondetectable. Petsonk
et al. (2000) investigated a group of new
workers exposed to MDI resins in a facility
designed for minimal airborne exposures and
noted new asthma-like respiratory symptoms
in 27% of the workers with the highest
potential for MDI exposure. These symptoms
were associated with liquid MDI skin expo-
sure, as evaluated by worker questionnaires
and workplace observations. 
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Table 2. Selected animal models of isocyanate asthma: sensitization via skin.
End points (inﬂammation, 
Compound, Sensitization via skin  Inhalation challenge airway responsiveness, 
reference Animal Frequency/form Dose (µmol NCO) Frequency/form/route/timing Dose isocyanate antibodies, other)
TDI
Karol et al.  Guinea  Single; 1/day × 50 µL 1, 10, 25,  Various; ~ 7, 70, 174,  Once/inhalation/TDI vapor and  5 ppb TDI vapor and  ↑ Respiratory rate, ↑ TDI-IgE 
1981 pig 100% in OO 1,390 TDI-GSA conjugate aerosol,  12 µg/L air TDI-GSA antibodies 
2 weeks later
Erjefält and  Guinea  Twice; days 1 and 8; 1/day × 2 × ~ 278 = 556 Once; tracheal, TDI, day 15 ~ 1.4–4 pmol NCO ↑ Plasma exudation in lungs 
Persson 1992 pig 2 days ×100 µL 20% TDI in EA/OO (131I-albumin)
Scheerens  Mice  Short exp: 2/day × 2 days; Short exp: 2 × 55.6 = 111 Once; intranasal, 20 µL 1% TDI Intranasal  2.8  µmol  Short:  ↑ TDI-IgG, long: ↑ TDI-IgE
et al. 1999  BALB/c long exp: 1/ week × 6 weeks; Long exp: 6 × ~ 28 = 167 in EA/OO and ear 20 µL 0.5%  NCO + ear 1.4 µmol  and TDI-IgG, ↑ in vivo tracheal 
both: × 200 µL 1% TDI in Ace/OO in Ace; day 8 or day 42  NCO hyperresponsiveness
Vanoirbeek  Mice  Variable; once (1% TDI) or  1% TDI: 5.6 × (1+1) = 11.2; Once; intranasal, 20 µL 0.1% 0.28 µmol NCO ↑ Airway responsiveness, 
et al. 2004  BALB/c 1/day × 3 days (1, 2, 3); 40 µL  0.3% TDI: ~ 1.7 × (3 + 1)  TDI in Ace/OO, day 10 ↑ mixed Th1/Th2 lung 
0.3% or 3% TDI in Ace/OO,  = 6.7; 3% TDI: inﬂammation,  ↑ total IgE, 
+ repeat on day 7 16.7 × (3 + 1) = 66.8 greater response with lower 
skin dose; timing and freq 
skin exposure important
Ban et al.  Mice  Single; 50 µL 1% TDI in Ace/OO on  7 on skin + 1.4  Trachea instillation with 50 µL  3 × 0.7 = 2.1 µmol  Lung Th2 inﬂammation, 
2006  BALB/c day 0, then tracheal instillation  tracheal instillation 0.1% TDI in OO, on days 18,  NCO ↑ TDI-IgE, only skin sensit 
with 50 µL 0.2% TDI in OO on  28, 31 induced Th2 asthma-like 
day 5 responses
HDI
Herrick et al. Mice  Twice; 50 µL 0.01 or 1% HDI in  1.2 and 12.4 Intranasal; 50 µL HDI-MSA  100 µg Lung and BAL Th2 inﬂammation,
2002  BALB/c 4:1 A:OO on days 0 and 7 (2 µg/µL) on days 14, 15, 18,  ↑ IgE, ↑ HDI-IgG, lower sensit 
19 dose, more lung inﬂammation
MDI
Rattray et al.  Guinea  Single, variable; 400 µL of 10, 30,  320, 959, 3,195 Once; inhalation of MDI  26–36 mg/m3 ↑ Respiratory rate, ↑ MDI-IgG1,
1994  pig or 100% MDI in CO aerosol on day 21 inhalation failed to induce 
sensit
Abbreviations: ↑, increase; Ace, acetone; Alb, albumin; BAL, bronchoalveolar lavage; CO, corn oil; EA, ethyl acetate; exp, exposure; Freq, frequency; GSA, guinea pig serum albumin;
MSA, mouse serum albumin; OO, olive oil; sensit, sensitization. Leanerts-Langanke (1992) described an
investigation of about 500 coal mine workers
who used MDI for rock consolidation.
Quantitative air sampling results were at or
below the detection limit (1 ppb). MDI skin
exposure was reported in about half the work-
ers; MDI-IgE was detected in several workers;
and 2 were diagnosed with isocyanate asthma
based on a positive speciﬁc challenge. Elevated
levels of MDI metabolites in urine were found
in 6 of 8 workers seen after “massive skin con-
tamination.” The authors concluded that skin
could be an important route of exposure, lead-
ing to sensitization and asthma. 
Bernstein et al. (1993) studied a cohort of
243 workers in a urethane molding plant that
consistently maintained low MDI airborne
exposures (< 5 ppb). Isocyanate asthma and/or
sensitization (MDI-IgE) was diagnosed in sev-
eral workers, most of whom were reported
likely to have had MDI skin exposure.
Our group has characterized workplace iso-
cyanate exposures in a population of > 200
auto body shop workers with isocyanate-
speciﬁc immune responses but without docu-
mented isocyanate asthma (Redlich et al. 2001;
Woskie et al. 2004). Respiratory and skin
exposures were estimated for each of the work-
ers, based on exposure algorithms. HDI-
specific IgG, present in 21% of the workers,
was strongly associated with inhalation expo-
sure, but skin exposure also contributed (Stowe
et al. 2006). We have also detected MDI-spe-
ciﬁc IgG in > 30% of about 100 workers in a
factory that uses MDI to produce polyurethane
coated fabrics. MDI air monitoring data have
consistently been very low, and MDI skin
exposure has been documented by worker
questionnaires and direct observation (Liss
et al. 2006). In both work settings, isocyanate
skin exposure appeared to contribute to the
development of isocyanate-speciﬁc IgG, which
has been associated with isocyanate exposure
(Welinder et al. 1988; Wisnewski et al. 2004;
Ye et al. 2006). 
Studies investigating the respiratory expo-
sure conditions that lead to isocyanate asthma
also suggest a potential role for skin exposure.
Fewer cases of isocyanate asthma have generally
been reported in settings with lower respiratory
exposures, but cases continue to occur in set-
tings with consistently low reported air levels
(Baur 2003; Tarlo et al. 1997). Skin exposure
(Bernstein et al. 1993; Leanerts-Langanke
1992) or intermittent peak exposures, which
could also entail both respiratory and skin
exposure (Tarlo et al. 1997), have been consid-
ered important contributing factors in such
cases. Typically, such exposures are unpre-
dictable and frequently accidental, making
them difﬁcult to investigate and quantify. 
For cutaneous allergen exposure in gen-
eral, the likelihood of sensitization in a suscep-
tible person is thought to depend on several
factors including the total dose and concentra-
tion of allergen, skin surface area, and the fre-
quency of repeated contact with the skin, with
determinants of individual susceptibility
remaining poorly defined (Basketter et al.
2006; Boukhman and Maibach 2001). There
are insufﬁcient data to address isocyanate skin
exposure–response relationships in humans;
however, as noted above, in animal models
relatively small skin doses can induce sensitiza-
tion, and dose–response relationships may
be variable. 
Regulatory standards for isocyanate skin
exposure. The regulatory framework for skin
exposure to chemicals is underdeveloped com-
pared with inhalation exposures. Chemicals
that pose a health hazard through skin exposure
are commonly assigned two qualitative descrip-
tors: a “skin” notation, referring to absorption
of the chemical through the skin, and/or a “sen-
sitizer” notation for an agent with the potential
to produce sensitization regardless of the expo-
sure route (respiratory, skin, or conjunctiva)
[American Conference of Governmental
Industrial Hygienists (ACGIH) 2006].
In the United States, although NIOSH
recommends prevention of isocyanate skin
exposure, skin exposure is not regulated. No
“skin” notation exists for diisocyanates or
polyisocyanates, except for the NIOSH
(2005) recommendation for IPDI.
Although data confirming the risks of
human isocyanate skin exposure remain lim-
ited, there is sufﬁcient information to recom-
mend prevention of skin exposure. Such
recommendations are now being made in
material safety data sheets and are beginning
to appear in the medical literature (Bakke
et al. 2006; Baur 2003). Wider dissemination
and improved hazard communication of this
information by occupational and environ-
mental health professionals, as well as better
personal protection among workers, are
needed. Inclusion of “skin” notation may
encourage such protection for all isocyanates
(diisocyanates and polyisocyanates). 
Research needs. In this review we highlight
several important areas for further research
regarding isocyanate skin exposure, ideally
using multidisciplinary approaches involving
animal models and clinical and epidemiologic
investigations. Such approaches should lead to
a better understanding of the mechanistic
pathways that result in isocyanate asthma and
the role of skin exposure in this process. A key
research need not unique to issues regarding
skin exposure is the development of a good
marker of isocyanate sensitization or “pre-clin-
ical” asthma that correlates well with the sub-
sequent development of asthma. Such a
marker would greatly enhance isocyanate
research, including elucidation of exposure–
response relationships, and facilitate diagnosis
and prevention. 
There is a need to better assess isocyanate
skin exposures in the workplace and other
environments and to incorporate these expo-
sure data into epidemiologic and clinical stud-
ies. The typically more sporadic nature of such
exposures further complicates real-world expo-
sure assessment and requires algorithms that
employ a combination of daily activities
(diaries), questionnaires, and task-based expo-
sure data. Development of route-speciﬁc bio-
markers, such as those specific for skin or
lung, would greatly facilitate isocyanate expo-
sure assessment. Skin exposure methodologies
and biomarkers of exposure can be further
developed and validated using integrated
animal models. 
Numerous host and environmental deter-
minants of isocyanate skin exposure have
barely been investigated. Isocyanate skin
absorption likely depends on various factors
including molecular size and coexposures
(e.g., polyols, solvents, and other additives),
which could enhance absorption. The role of
host factors, such as history of eczema and
hand washing, warrant further investigation,
as does the effectiveness of gloves, protective
clothing, and other preventive strategies.
Given the widespread and growing use of
polyurethane consumer products, research is
also needed to investigate potential environ-
mental exposures from these consumer prod-
ucts, as well as exposures that may occur when
isocyanate products are manipulated (ground,
cut, drilled) or undergo thermal degradation
as in fires. Further research investigating the
curing process is also warranted because
incompletely cured products could be a poten-
tial and unexpected source of skin exposure
(Bello et al., in press).
Conclusion
Isocyanates, primarily diisocyanate monomers
and polyisocyanates, are a leading cause of
occupational asthma. Human skin exposure
to isocyanates has been underrecognized and
can occur in various workplace and environ-
mental settings. Multiple lines of evidence
from animal studies and clinical, epidemio-
logic, and biomarker studies, as well as anec-
dotal evidence, indicate that in certain
exposure settings human skin likely is an
important route of isocyanate exposure and
can contribute to the development of iso-
cyanate asthma. This presumably occurs by
isocyanate skin exposure inducing systemic
sensitization, which then leads to isocyanate
asthma after inhalation exposure; however,
the mechanistic pathways involved remain
poorly deﬁned. Further research is needed to
address issues regarding isocyanate skin expo-
sure in the growing polyurethane industry. In
spite of substantial research needs, sufficient
evidence already exists to justify greater
emphasis on the potential risks of isocyanate
Skin exposure to isocyanates 
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exposures. We conclude with the visionary
statement of Munn (1965): 
The more one knows about these fascinating com-
pounds [isocyanates] the more fascinated one
becomes. So diverse are their uses, it is obvious that
they are here to stay, and that their use will increase.
So numerous have been the accounts of their
effects, it is obvious not merely they are hazardous
but that the nature and extent of their hazard has
not always been fully appreciated.
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